Bristol-Myers Squibb will acquire biopharmaceutical firm Inhibitex for $2.5 billion.
Read the full article:
Atlanta Business Chronicle
Bristol-Myers Squibb will acquire biopharmaceutical firm Inhibitex for $2.5 billion.
Read the full article:
Atlanta Business Chronicle